TY - JOUR
TI - Rotavirus vaccination in Europe: drivers and barriers
AU - Parez, N.
AU - Giaquinto, C.
AU - Du Roure, C.
AU - Martinon-Torres, F. and
AU - Spoulou, V.
AU - Van Damme, P.
AU - Vesikari, T.
JO - The Lancet Infectious Diseases
PY - 2014
VL - 14
TODO - 5
SP - 416-425
PB - Elsevier Sci Ltd, Exeter, United Kingdom
SN - null
TODO - 10.1016/S1473-3099(14)70035-0
TODO - null
TODO - Rotavirus gastroenteritis is a vaccine-preventable disease that confers
a high medical and economic burden in more developed countries and can
be fatal in less developed countries. Two vaccines with high efficacy
and good safety profiles were approved and made available in Europe in
2006. We present an overview of the status of rotavirus vaccination in
Europe. We discuss the drivers (including high effectiveness and effect
of universal rotavhus vaccination) and barriers (including low awareness
of disease burden, perception of unfavourable cost-effectiveness, and
potential safety concerns) to the implementation of universal rotavirus
vaccination in Europe. By February, 2014, national universal rotavirus
vaccination had been implemented in Belgium, Luxembourg, Austria,
Finland, Greece, Luxembourg, Norway, and the UK. Four other German
states have issued recommendations and reimbursement is provided by
sickness funds. Other countries were at various stages of recommending
or implementing universal rotavirus vaccination.
ER -